Related references
Note: Only part of the references are listed.Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
Nicholas D. James et al.
LANCET (2016)
Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data
Claire L. Vale et al.
LANCET ONCOLOGY (2016)
Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer
Himisha Beltran et al.
NATURE MEDICINE (2016)
Integrating outpatient palliative care into a metastatic breast oncology clinic.
Rebecca Small et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
The evolutionary history of lethal metastatic prostate cancer
Gunes Gundem et al.
NATURE (2015)
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
Christopher J. Sweeney et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Aggressive Variants of Castration-Resistant Prostate Cancer
Himisha Beltran et al.
CLINICAL CANCER RESEARCH (2014)
Optimal management of metastatic castration-resistant prostate cancer: Highlights from a European Expert Consensus Panel
John M. Fitzpatrick et al.
EUROPEAN JOURNAL OF CANCER (2014)
Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial
Peter Hoskin et al.
LANCET ONCOLOGY (2014)
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy REPLY
Tomasz M. Beer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
T. M. Beer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer
Ana M. Aparicio et al.
CLINICAL CANCER RESEARCH (2013)
Molecular States Underlying Androgen Receptor Activation: A Framework for Therapeutics Targeting Androgen Signaling in Prostate Cancer
Peter S. Nelson
JOURNAL OF CLINICAL ONCOLOGY (2012)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the prostate cancer clinical trials working group
Howard I. Scher et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: A TAX327 study analysis
Andrew J. Armstrong et al.
CLINICAL CANCER RESEARCH (2007)
Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer
S Halabi et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration
O Smaletz et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Share Paper
